>> I wouldn't say a rejection is bad for genr. Wouldn't that open up Pfizer as a potential partner? <<
Then your expectation set is inconsistent with itself, as I had suggested.
You say that an unconditional thumbs-up by the panel is good for GENR, but the opposite outcome is also good (or at least not bad). That’s mathematically nonsensical.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”